Project 1: Radical pleurectomy (RP) with intraoperative, pleural photodynamic therapy (pPDT) and post-operative chemotherapy produces an unprecedented median overall survival (OS) of over 41 months in patients with locally advanced, epithelial malignant pleural mesothelioma (MPM). Unlike most surgical series, >50% of RP/pPDT patients survive more than 12 months after MPM relapse;however, a subset of patients who experience early local relapse (LR, <12 mo after RP/pPDT) exhibit a rapidly progressive and fatal clinical course. One major uncertainty in these data is the how much pPDT contributes to the remarkably good outcomes. This uncertainty provides the motivation for Aim 1 of this Project, which is to perform a randomized Phase II trial in patients with epithelial MPM that will test the hypothesis that pPDT improves overall survival when added to RP followed by chemotherapy. Another uncertainty involves understanding the potential mechanisms underlying the poor prognosis for patients with early LR. Thus, Aim 1 also serves as a point of integration between the projects and cores by providing opportunities for analysis of patient-specific factors that relate to RP/pPDT patient outcome, including factors critical to pPDT dose such as light delivery and photosensitizer uptake in spatially corresponding areas. Finally, the impact of inter- and intra-patient heterogeneity on the conduct of the trial, the analysis of the data and the outcome of the patients remains unclear. Project 1 will work with the Physics and Dosimetry Core A, the Animal and Pathology Core C and the Administrative Core D to minimize the intrinsic heterogeneity of clinical practice and sample acquisition through the application of documents and protocols to standardize procedures across the Program Project. Finally, in Aim 2, the impact of heterogeneity in pPDT dose and expression of tumor-intrinsic pPDT resistance factors on patient outcome will be evaluated.
This aim will test the hypothesis that time-to-local recurrence after pPDT is a function of the intra-patient heterogeneity in delivered pPDT dose (photosensitizer uptake * light fluence). We also test whether the combination of adverse tumor features (molecular/vascular phenotypes associated with PDT resistance) and large intra-patient heterogeneity in pPDT dose identifies a subset of patients at high risk for poor outcome.
Project 1 Narrative This project will more clearly define the role of pPDT in managing MPM and may shift treatment paradigms for this disease. We will also provide data and samples that will later feed back into the development of novel clinical trials. Moreover, by establishing the clinical value of pPDT, this project will help to remove a critical barrier to the more widespread application of resection with pPDT as a treatment paradigm in cancers with high rates of local recurrence following surgery.
|Davis 4th, Richard W; Snyder, Emma; Miller, Joann et al. (2018) Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy. Photochem Photobiol :|
|Cramer, Gwendolyn; Simone 2nd, Charles B; Busch, Theresa M et al. (2018) Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma. J Thorac Dis 10:S2565-S2573|
|Ong, Yi Hong; Padawer-Curry, Jonah; Finlay, Jarod C et al. (2018) Determination of optical properties, drug concentration, and tissue oxygenation in human pleural tissue before and after Photofrin-mediated photodynamic therapy. Proc SPIE Int Soc Opt Eng 10476:|
|Ong, Yi Hong; Kim, Michele M; Huang, Zheng et al. (2018) Reactive Oxygen Species Explicit Dosimetry (ROSED) of a Type 1 Photosensitizer. Proc SPIE Int Soc Opt Eng 10476:|
|Zhu, Timothy C; Kim, Michele M; Padawer, Jonah et al. (2018) Light Fluence Dosimetry in Lung-simulating Cavities. Proc SPIE Int Soc Opt Eng 10476:|
|Chandra, Abhishek; Wang, Luqiang; Young, Tiffany et al. (2018) Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis. FASEB J 32:52-62|
|Ong, Yi Hong; Finlay, Jarod C; Zhu, Timothy C (2018) Monte Carlo modelling of fluorescence in semi-infinite turbid media. Proc SPIE Int Soc Opt Eng 10492:|
|Yan, Lesan; Amirshaghaghi, Ahmad; Huang, Dennis et al. (2018) Protoporphyrin IX (PpIX)-Coated Superparamagnetic Iron Oxide Nanoparticle (SPION) Nanoclusters for Magnetic Resonance Imaging and Photodynamic Therapy. Adv Funct Mater 28:|
|Dimofte, Andreea; Finlay, Jarod; Ong, Yi Hong et al. (2018) A quality assurance program for clinical PDT. Proc SPIE Int Soc Opt Eng 10476:|
|Ahn, Peter H; Finlay, Jarod C; Gallagher-Colombo, Shannon M et al. (2018) Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy. Photodiagnosis Photodyn Ther 21:28-35|
Showing the most recent 10 out of 127 publications